Cuprina Holdings (Cayman) Limited Stock Price, News & Analysis

Cuprina Holdings (NASDAQ:CUPR) has issued a statement addressing recent unusual trading volatility in its stock. The company emphasized that it remains fully operational and legally compliant, with no known operational reasons or material adverse events causing the stock fluctuations.

CEO David Quek confirmed that no initial shareholders or founding team members have sold their stock in the past week. The company is progressing with key milestones, including FDA clearance submission for medical maggot therapy, expansion into the GCC region, and exploring potential joint ventures in chronic wound management.

Cuprina, which completed its IPO earlier this year, maintains its commitment to transparency and execution of its business plan while focusing on advancing its biotherapeutic pipeline.

Cuprina Holdings (Nasdaq: CUPR) has made two significant announcements in the bio-therapeutics space. First, the company appointed Dr. Ronald A. Sherman, a pioneer in medical maggot therapy, as Medical and Scientific Director effective September 2025. Second, Cuprina secured a license for Dr. Sherman's 2004 FDA clearance to market Lucilia sericata Medical Maggots™ in the United States.

Dr. Sherman will lead clinical initiatives, develop training frameworks, and provide regulatory guidance. Cuprina is also pursuing FDA clearance for another maggot species, Lucilia cuprina, with potential approval expected within 90 business days. The U.S. market for maggot debridement therapy was valued at $13.9 million in 2024 and is projected to reach $24.8 million by 2030, growing at a 10.1% CAGR.

Cuprina Holdings (Nasdaq: CUPR) has provided updates on three one-year research studies with leading educational institutes focused on developing collagen peptide molecules from American bullfrog skin. The company has made significant progress in these collaborations:

With Republic Polytechnic, Cuprina identified methods to generate peptides for cosmeceutical applications. The collaboration with the Institute for Health Innovation and Technology at NUS is exploring bullfrog collagen peptides for 3D printable wound care dressings, including microneedling patches. The partnership with the Singapore Institute of Technology aims to produce superior powdered bullfrog collagen peptides.

Research has shown that bullfrog-derived collagen achieved 90% wound closure in 24 hours compared to 34% for bovine collagen. The global collagen peptides market is projected to grow from $699 million in 2023 to $922 million in 2028, at a CAGR of 5.7%.

Cuprina Holdings (NASDAQ: CUPR) has announced two significant developments in the MENA region. First, its 49%-owned associate, Cuprina MENA Co. Ltd, has completed setting up a laboratory in Saudi Arabia for manufacturing MEDIFLY maggot debridement therapy for chronic wound treatment. The company is now pursuing regulatory approvals, including Saudi FDA license and ISO 13485 certification. Second, Cuprina MENA has obtained exclusive rights from Biopharm UK Ltd to distribute medicinal leeches across GCC countries. These leeches are used to treat various medical conditions including venous congestion, post-surgical healing, osteoarthritis symptoms, and veterinary applications, particularly for treating polycythaemia vera.

Cuprina Holdings (NASDAQ: CUPR) announced the successful closing of its underwriter's over-allotment option following its IPO, selling an additional 450,000 Class A ordinary shares at $4.00 per share. Combined with the previously announced IPO proceeds of $12 million, the company has raised total gross proceeds of $13.8 million. R. F. Lafferty & Co. served as the sole book-running manager for the offering.

Cuprina, a biomedical and biotechnology company, focuses on developing products for chronic wound management, infertility treatments, and cosmeceuticals for the health and beauty sector. The offering was conducted under the company's Form F-1 registration statement, which became effective on March 31, 2025.

Cuprina Holdings (NASDAQ: CUPR) has completed construction and obtained ISO 13485 certification and a dealer license for its new IVF media production facility in Singapore. The facility, built in collaboration with Ferti-Craft, will produce 14 SKUs of IVF media products essential for in-vitro fertilization. The ISO certification was issued by UKAS, while the dealer license came from Singapore's HSA. The facility aims to begin commercial production by Q4 2026, initially targeting Singapore before expanding to ASEAN countries, Middle East, and other global markets. The collaboration leverages Ferti-Craft's expertise in human assisted reproductive technology and Cuprina's experience with ISO 13485-compliant facilities. This development positions both companies to tap into the growing ART market, valued at $34.7 billion in 2023 and projected to reach $62.8 billion by 2032 with a 6.9% CAGR.

Cuprina Holdings (Nasdaq: CUPR) has successfully completed its Initial Public Offering (IPO), raising $12.0 million in gross proceeds through the sale of 3,000,000 Class A Ordinary Shares at $4.00 per share. Trading began on NASDAQ on April 10, 2025, under the symbol 'CUPR'.

The company, focused on chronic wound management and cosmeceuticals, plans to utilize the net proceeds for:

• Market expansion
• R&D activities and product portfolio expansion
• Brand awareness building
• Equipment and infrastructure investment
• Working capital and general corporate purposes

R. F. Lafferty & Co. served as the sole book-running manager for the offering. The company's strategy centers on developing sustainable, nature-derived products for treating chronic wounds, targeting the growing market driven by aging populations and increasing prevalence of diabetes, obesity, and cardiovascular ailments.

Cuprina Holdings (CUPR), a biomedical and biotechnology company focused on chronic wound management and cosmeceuticals, has announced the pricing of its Initial Public Offering (IPO). The company is offering 3,000,000 Class A Ordinary Shares at $4.00 per share, with an additional 45-day option for underwriters to purchase up to 450,000 shares.

The IPO is expected to generate gross proceeds of $13.80 million (assuming full exercise of the over-allotment option), before deducting underwriting costs and offering expenses. Trading will commence on NASDAQ under the symbol 'CUPR' on April 10, 2025, with the offering scheduled to close on April 11, 2025. R. F. Lafferty & Co. is serving as the sole book-running manager for the offering.